|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:Novartis'_influenza_vaccine_business
gptkb:Talecris_Biotherapeutics
gptkb:Vifor_Pharma
|
|
gptkbp:awards
|
Best Places to Work
Sustainability Awards
Top 100 Global Innovators
|
|
gptkbp:ceo
|
gptkb:Paul_Perreault
|
|
gptkbp:clinical_trial
|
biomarker studies
real-world evidence studies
multiple ongoing
global clinical trials
patient-centered studies
therapeutic area studies
|
|
gptkbp:collaborations
|
government agencies
non-profit organizations
biopharmaceutical companies
various academic institutions
|
|
gptkbp:employees
|
over 25,000
|
|
gptkbp:focus
|
hematology
infectious diseases
immunology
transplantation
cardiovascular
respiratory
|
|
gptkbp:founded
|
gptkb:1966
1916
|
|
gptkbp:founder
|
gptkb:Sir_Gustav_Nossal
|
|
gptkbp:global_presence
|
over 60 countries
|
|
gptkbp:headquarters
|
gptkb:Melbourne,_Australia
gptkb:Parkville,_Australia
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CSL Limited
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:invention
|
over 1,000
|
|
gptkbp:market_cap
|
approximately $100 billion (2021)
|
|
gptkbp:partnership
|
gptkb:University_of_Melbourne
gptkb:Monash_University
gptkb:Australian_Red_Cross_Blood_Service
|
|
gptkbp:philanthropy
|
gptkb:CSL_Behring_Foundation
community health initiatives
disaster relief efforts
education programs
support for medical research
|
|
gptkbp:products
|
plasma-derived therapies
recombinant therapies
|
|
gptkbp:research_and_development
|
$1.5 billion (2021)
|
|
gptkbp:revenue
|
$10 billion (2021)
$10.1 billion (2021)
|
|
gptkbp:stock_exchange
|
gptkb:ASX
|
|
gptkbp:subsidiary
|
gptkb:CSL_Seqirus
gptkb:CSL_Behring
|
|
gptkbp:sustainability_initiatives
|
community engagement
ethical sourcing
employee well-being
environmental responsibility
|
|
gptkbp:bfsParent
|
gptkb:Australian_Securities_Exchange_(ASX)
|
|
gptkbp:bfsLayer
|
5
|